Ranbaxy introduces Osonide inhaler

Ranbaxy Laboratories Ltd has announced the launch of its branded Osonide (Ciclesonide) Inhaler for the first time in India. The inhaler is touted as a once a day treatment for asthma.

The product is pressurised metered dose inhalers of strengths 160mcg and 80mcg, stated a company release. The dosages are priced at Rs 290 and Rs 240 respectively.

"We have entered a new segment, with this product, that is expanding rapidly. It would be a niche strength in our product portfolio," said a Ranbaxy spokesperson.

Osonide HFA Inhaler, as opposed to conventional CFC (chloro fluoro carbon propellant) inhaler, is environment friendly, has dosage convenience and ensures better delivery in patients' airways on account of being activated only in the lungs, thereby reducing side effects.

Speaking on the occasion, Sanjeev I Dani, regional director, India & Middle East, Ranbaxy Labs said, "The introduction of Osonide inhaler showcases our strength in developing innovative solutions for superior management of asthma therapy."

India at present has an estimated 15-20 million asthmatic patients and the estimated prevalence rate in 5-11 year-old children is between 10 and 15 per cent. The classified triggers for asthma include environment pollutants, molds, dust mites, certain food etc.